Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
| ▸ | SORD | Q00796 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20443214 | 0.85 | NPC1 (0.37) | LMNAHTTNPC1RAB9AKLF5 | |
| SCHEMBL12988375 | 0.82 | OGA (0.46) | ACHELMNAHTTNPC1RAB9A | |
| SCHEMBL458210 | 0.80 | PDE10A (0.39) | LMNAHTTNPC1RAB9AMEN1 | |
| SCHEMBL20255732 | 0.80 | CDK4 (0.40) | HRH3 | |
| SCHEMBL24126287 | 0.79 | LMNA (0.57) | LMNAHTTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL20046660 | 0.79 | LMNA (0.37) | ACHELMNAHTTNPC1RAB9A | |
| SCHEMBL12988268 | 0.78 | HRH3 (0.54) | LMNAHTTNPC1RAB9AKLF5 | |
| SCHEMBL23733444 | 0.77 | KDM4E (0.47) | NPC1RAB9AHRH3HRH4 | |
| SCHEMBL12989025 | 0.76 | ACHE (0.38) | ACHEHRH3HRH4SORD | |
| SCHEMBL21414326 | 0.76 | BPTF (0.57) | HTTMEN1KMT2AHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200155689-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200155689-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | CRBN, CBL, MDM2 | ACHE 2447/4885LMNA 3085/4885HTT 1235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.